Answers are grounded in this paper and cite their sources.
Background Toxoplasma gondii infects about one-third of humans and causes severe disease in immunocompromised individuals, congenitally infected neonates and livestock, yet no licensed human vaccine exists. We hypothesized that the obstacle is the absence of a standardized framework for comparing translational readiness across this heterogeneous preclinical literature. Methods We conducted a PRISMA 2020–compliant systematic review of T. gondii vaccine studies published January 2015–March 2026 (searched 11 April; PubMed/MEDLINE updated 6 July 2026). Four databases (PubMed/MEDLINE, OpenAlex, Google Scholar, and Cochrane CENTRAL) plus the update yielded 3,583 records (2,304 after deduplication); 305 met all criteria. We extracted predefined variables per study and scored translational readiness with BRIDGE (0–22), a five-domain rubric whose Translation-Relevant (TR) tier applies conjunctive per-domain minima, preventing compensation between domains. Results Across 16 platforms, BRIDGE ranged 0–14. Only 2 of 305 met TR criteria, both live-attenuated; SYRCLE risk of bias was unclear in 98.0%, GLP documentation absent corpus-wide. In 88 studies challenging a type I and a non-type-I strain in the same experiment, all 42 discordant studies favored the non-type-I strain (exact p = 4.5 × 10−13). Against type I, the result was delayed death, not survival. The direction holds under all four definitions, with one exception; the two strictest leave too few discordant pairs for significance. Among oral-challenge studies measuring each marker, CD8 + elevation was associated with protection ( OR = 11.08, n = 39; not surviving multiple-testing correction), but 20 of 21 High Partial outcomes there share one senior (last) author, hence not generalizable. IFN-γ, elevated in 77.7%, is necessary for resistance; its inverse estimate there ( OR = 0.07) arises entirely within one laboratory, not a biological signal. Conclusions The literature shows high volume with severe regulatory-readiness reporting deficits. All inferential findings are hypothesis-generating. Four priorities emerge: (i) oral challenge with Type II tissue cysts and ≥60-day follow-up; (ii) the challenge strain genotype reported as a primary design variable; (iii) quantitative reporting of the CD8 + phenotype and cytotoxic T-lymphocyte function; and (iv) feline, livestock, and congenital endpoints within an explicit One Health framework. BRIDGE and a Minimum Immune Reporting Data Set (MIRDS) are proposed as reporting tools.
No takes yet. Share an insight, caveat, or question.
León-Garduño et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: